<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02531737</url>
  </required_header>
  <id_info>
    <org_study_id>I14041/REFRACT</org_study_id>
    <nct_id>NCT02531737</nct_id>
  </id_info>
  <brief_title>Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer</brief_title>
  <acronym>REFRACT</acronym>
  <official_title>Multicenter Phase II Trial of Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With no Squamous Non Small Cell Lung Cancer Refractory to First Line Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether nintedanib (vargatef®) combined with
      docetaxel are effective in second line of treatment in patients with no squamous non small
      cell lung cancer refractory to first line chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      59 Patients with histologically documented stage IV NSCLC no squamous, after failure of first
      line chemotherapy and refractory (progressive disease during first line chemotherapy), will
      be enroled to receive docetaxel :75 mg/m² IV day 1 every 3 weeks with nintedanib
      (vargatef®):200 mg X 2/day per os day2-day21.

      Tumor response (according to RECIST) will be assessed via computed tomography or magnetic
      resonance imaging scan every 6 weeks (evaluation of PFS) following completion of
      chemotherapy.

      Adverse events (AEs) were graded according to the National Cancer Institute Common Toxicity
      Criteria, version 4.0

      Quality of life(EQ5-D ) will be assessed every 6 weeks during chemotherapy. Tolerability will
      be assessed at each visit based on Common Terminology Criteria for Adverse Events (CTCAE),
      v4.0 criteria.

      Total study duration per patient: approximately 12 months .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>median progression free survival</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>median progression free survival</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity (NCIC-CTC version 4.0 criteria)</measure>
    <time_frame>Every 3 weeks during treatment up to 12 months from inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (EQ5-D questionnaire)</measure>
    <time_frame>every 6 weeks up to 12 months from inlcusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">59</enrollment>
  <condition>Lung Neoplasms</condition>
  <arm_group>
    <arm_group_label>traitment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated to oral nintedanib (vargatef®) 400 mg/d on days 2 to 21 of a 3-week cycle including docetaxel 75 mg/m2 by intravenous infusion on day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vargatef®</intervention_name>
    <description>Patients will be treated to oral nintedanib (vargatef®) 400 mg/d on days 2 to 21 of a 3-week cycle</description>
    <arm_group_label>traitment</arm_group_label>
    <other_name>Nintedanib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Patients will be treated to IV docetaxel 75 mg/m² on day 1 of evry 3-week cycle</description>
    <arm_group_label>traitment</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed non-squamous NSCLC,

          -  Metastatic NSCLC of stage IV (according to American Joint Committee on Cancers) or
             recurrent NSCLC)

          -  Patients without activating epidermal growth factor receptor (EGFR) mutation

          -  Patients without anaplastic lymphoma kinase (ALK) rearrangement

          -  Patients must have measurable lesion by RECIST 1.1

          -  Refractory disease defined by documented progression during the first-line
             chemotherapy based on a platinum doublet and third-generation drug (four or less
             cycles) according to RECIST V.1.1

          -  Age ≥18 years and &lt; 75 years

          -  Performance status (PS) 0-1

          -  Life expectancy of more than 12 weeks.

          -  No history of other malignancy within the last 5 years, except for adequately treated
             carcinoma in situ of the cervix or basal cell or spinocellular carcinoma of the skin.

          -  Adequate organ function, evidenced by the following laboratory results within 3 weeks
             prior to randomization: Normal hepatic function: bilirubin &lt; 1.5 x N, ALT (alanine
             transaminase) and AST (aspartate aminotransferase ) &lt; 2.5 x N or &lt;5 x N in case of
             liver metastasis

          -  Normal renal function (calculated creatinine clearance ≥ 45 mL/min).

          -  Normal Calcemia

          -  Normal haematological function (polynuclear neutrophils &gt; 1.5 G/l, platelets &gt; 100
             G/l).

          -  Anticoagulation with a vitamin K antagonist and low-molecular-weight heparin (LMWH) is
             authorized.

          -  Antiplatelet treatment (aspirin authorized if &lt; 325 mg/d)

          -  Treatment with dipyridamole, ticlopidine, clopidogrel is not authorized

          -  Women of child bearing potential must use double effective contraception.

          -  Men might be surgically sterile or accept to use an effective contraceptive procedure
             during and until 6 months after the treatment.

          -  Written informed consent to participate in the study.

        Exclusion Criteria:

          -  Known hypersensitivity to the trial drugs (nintedanib (vargatef®), docetaxel), peanut,
             soya, to their excipients

          -  Controlled disease after first line treatment

          -  Contra indication to the use of the backbone treatment

          -  Patients who were withdrawn from first line treatment due to toxicity without
             documented disease progression or who received placebo (in the context of a clinical
             trial) as prior treatment are not eligible.

          -  Previous treatment with docetaxel

          -  Small-cell lung cancer, bronchioloalveolar cancer, neuroendocrine cancer.

          -  Previous therapy with vascular endothelial growth factor (VEGF) inhibitors except
             bevacizumab

          -  Centrally located tumour with radiographic evidence of local invasion of local blood
             vessels

          -  Radiographic evidence of cavitary or necrotic tumours at screening

          -  Chemo-, hormone-, radio-(except for brain and extremities) or immunotherapy or therapy
             with monoclonal antibodies or small tyrosine kinase inhibitors within the past 4 weeks
             prior to treatment with the trial drug.

          -  Toxicity non resolute due to prior treatment &gt; grade I (except alopecia).

          -  Radiotherapy (except extremities) within the past 3 months prior to baseline imaging

          -  Persistence of clinically relevant therapy related toxicity from previous radiotherapy

          -  Active brain metastases (e.g. stable for &lt;4 weeks, no adequate previous treatment with
             radiotherapy, symptomatic, requiring treatment with anti-convulsants; dexamethasone
             therapy will be allowed if administered as stable dose for at least one month before
             inclusion).

          -  Uncontrolled arterial hypertension.

          -  Concurrent radiotherapy, except for palliative bone irradiation.

          -  Other concurrent severe illnesses (congestive heart failure, unstable angina,
             significant arrhythmia or myocardial infarction less than 12 months before study
             entry).

          -  Stroke less than 6 months before study entry.

          -  Psychiatric or neurological disorders preventing the patient from understanding the
             nature of the trial

          -  Grade &gt;=1 peripheral neuropathy

          -  Uncontrolled infection.

          -  Caval syndrome

          -  Other organic disorders preventing inclusion in the trial

          -  Malabsorption syndrome

          -  Pregnancy and breast-feeding

          -  Surgery less than two months before study entry.

          -  Follow-up not feasible.

          -  Incarcerated and institutionalized
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain Vergnenegre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU LImoges</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean Bernard AULIAC, MD</last_name>
    <phone>0134974288</phone>
    <email>j-b.auliac@ch-mantes-la-jolie.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Veronique BLANC</last_name>
    <email>veroblanc.arcalib@orange.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH de Beauvais</name>
      <address>
        <city>Beauvais</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacky Crequet, MD</last_name>
      <phone>33.3 44 11 22 23</phone>
      <email>Jacky.crequit@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Jacky crequet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ch de Beauvais</name>
      <address>
        <city>Beauvais</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jacky CREQUIT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G. ROBINET, MD</last_name>
    </contact>
    <investigator>
      <last_name>G ROBINET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Monnet, MD</last_name>
      <phone>33.1 45 17 50 14</phone>
      <email>Isabelle.Monnet@chicreteil.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Monnet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Gap</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P Thomas, MD</last_name>
      <phone>33.4 92 40 61 26</phone>
      <email>pneumologie@ch-gap.fr</email>
    </contact>
    <investigator>
      <last_name>P Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. Vergnenegre, MD</last_name>
      <email>alain.vergnenegre@unilim.fr</email>
    </contact>
    <investigator>
      <last_name>B. Melloni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>A. Vergnenegre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Bretagne Sud</name>
      <address>
        <city>LOrient</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regine LAMY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Regine LAMY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier F. Quesnay</name>
      <address>
        <city>Mantes La Jolie</city>
        <zip>78200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JB. Auliac, MD</last_name>
      <phone>33 (0)1 34 97 40 70</phone>
      <email>j-b.auliac@ch-mantes-la-jolie.rss.fr</email>
    </contact>
    <investigator>
      <last_name>JB. Auliac, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HM</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fabrice BARLESI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne MADROSZYK, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anne MADROSZYK, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instiut de Cancérologie</name>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pierre FOURNEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Villefranche</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L falchero, MD</last_name>
      <phone>33.4 74 09 27 23</phone>
      <email>lfalchero@ch-villefranche.fr</email>
    </contact>
    <investigator>
      <last_name>L Falchero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2015</study_first_submitted>
  <study_first_submitted_qc>August 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2015</study_first_posted>
  <last_update_submitted>June 23, 2016</last_update_submitted>
  <last_update_submitted_qc>June 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

